Skip to main navigation Skip to search Skip to main content

Sodium glucose transporters inhibitors in the management of heart failure

  • Ram B. Singh
  • , Saibal Chakravorty
  • , Osama Elmaraghi
  • , Fateme Nabavizadeh
  • , Galaleldin Nagib Elkilany
  • , Meenakshi Jain
  • , Ashok K. Shukla
  • , Ajay Agarwal
  • , Amitabh Yaduvanshi
  • , Sanjay Mahajan
  • , Vikas K. Patel
  • Halberg Hospital and Research Institute
  • Metro Multispeciality Hospital
  • Naeem Diabetic Clinic
  • Emirates Hospital
  • Max Healthcare
  • Kailash Hospital and Heart Institute
  • Fortis Healthcare
  • Holy Family Hospital
  • Diabetes Clinic

Research output: Chapter in Book/Report/Conference proceeding › Chapter › peer-review

Abstract

There is evidence that sodium-glucose co-transporter 2 (SGLT2) inhibitors, reduce heart failure (HF) events and cardiovascular (CV) death in cohorts of HF, type 2 diabetes mellitus (T2DM), and those with chronic kidney disease (CKD). These beneficial effects appear to be consistent in patients with varying combinations of these diseases. SGLT2 inhibitors were also found to reduce the risks of clinical events in patients with HF, with early and sustained benefits regardless of ejection fraction and care setting. The clinicians have to be familiar with SGLT2 inhibitors because they are an important component of the modern foundational therapy of HF in order to implement their use and limit the potential adverse effects. This review aims to highlight the current evidence as a practical guide for the prescription of SGLT2 inhibitors in patients with HF, with reference to patient selection, initiation of treatment, and dosing.

Original languageEnglish
Title of host publicationPathophysiology, Risk Factors, and Management of Chronic Heart Failure
PublisherElsevier
Pages377-388
Number of pages12
ISBN (Electronic)9780128229729
ISBN (Print)9780128231111
DOIs
StatePublished - 1 Jan 2024

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Keywords

  • Cardiac hypertrophy
  • Cardiovascular outcome trials
  • SGLT2 inhibitors
  • chronic heart failure
  • clinical practical guide

Fingerprint

Dive into the research topics of 'Sodium glucose transporters inhibitors in the management of heart failure'. Together they form a unique fingerprint.

Cite this